Correlation Between I Mab and Apellis Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both I Mab and Apellis Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining I Mab and Apellis Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between I Mab and Apellis Pharmaceuticals, you can compare the effects of market volatilities on I Mab and Apellis Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in I Mab with a short position of Apellis Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of I Mab and Apellis Pharmaceuticals.
Diversification Opportunities for I Mab and Apellis Pharmaceuticals
-0.31 | Correlation Coefficient |
Very good diversification
The 3 months correlation between IMAB and Apellis is -0.31. Overlapping area represents the amount of risk that can be diversified away by holding I Mab and Apellis Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Apellis Pharmaceuticals and I Mab is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on I Mab are associated (or correlated) with Apellis Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Apellis Pharmaceuticals has no effect on the direction of I Mab i.e., I Mab and Apellis Pharmaceuticals go up and down completely randomly.
Pair Corralation between I Mab and Apellis Pharmaceuticals
Given the investment horizon of 90 days I Mab is expected to under-perform the Apellis Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, I Mab is 1.53 times less risky than Apellis Pharmaceuticals. The stock trades about -0.39 of its potential returns per unit of risk. The Apellis Pharmaceuticals is currently generating about 0.19 of returns per unit of risk over similar time horizon. If you would invest 2,734 in Apellis Pharmaceuticals on August 28, 2024 and sell it today you would earn a total of 457.00 from holding Apellis Pharmaceuticals or generate 16.72% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
I Mab vs. Apellis Pharmaceuticals
Performance |
| Timeline |
| I Mab |
| Apellis Pharmaceuticals |
I Mab and Apellis Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with I Mab and Apellis Pharmaceuticals
The main advantage of trading using opposite I Mab and Apellis Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if I Mab position performs unexpectedly, Apellis Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apellis Pharmaceuticals will offset losses from the drop in Apellis Pharmaceuticals' long position.The idea behind I Mab and Apellis Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.| Apellis Pharmaceuticals vs. Eliem Therapeutics | Apellis Pharmaceuticals vs. HCW Biologics | Apellis Pharmaceuticals vs. Scpharmaceuticals | Apellis Pharmaceuticals vs. Milestone Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Complementary Tools
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |